Press Releases and Blog
Blog
Matrix Global Advisors Touts Biosimilar Interchangeability Proposal in Biden Administration Budget – SSR Health: Biosimilar Competition Leads to Significant Decline in Net Prices on Brand Humira
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market and have advocated for policy changes that will increase generic and biosimilar uptake
ICYMI: RealClearHealth: Pat Toomey: Attacking PBMs Won’t Solve President Biden’s Inflation Problem
In case you missed it, former U.S. Senator Pat Toomey (R-PA) explains how the Biden Administration’s recent push targeting pharmacy benefit companies is a deflecting
ICYMI: Ike Brannon: Recently Proposed Federal And State Legislation To Constrain Pharmacy Benefit Managers Would Not Reduce Drug Costs
In case you missed it, Ike Brannon, health care economist and senior fellow at the Jack Kemp Foundation, published a new white paper, “Recently Proposed
Misguided Proposals Targeting Pharmacy Benefit Companies Would Increase Prescription Drug Costs for Patients, Take Away Options From Health Plan Sponsors, Like Employers and Unions
Proponents of policies targeting pharmacy benefit companies ignore the costly repercussions of undermining pharmacy benefit managers’ (PBMs) ability to secure savings that enable health plan
Renewed Congressional Focus On Patent Abuse Touts Proposals to Effectively Lower Prescription Drug Costs, Strengthen Competition in the Market
U.S. Senators Peter Welch (D-VT), Mike Braun (R-IN), and Amy Klobuchar (D-MN) recently introduced legislation that will crack down on drug companies’ patent abuse, specifically patent
ICYMI: 2021 House Oversight Committee Report Concluded Rebates Are Uncorrelated With Drug Prices
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with
Press Releases
PCMA Report Details Increased Costs Associated with Legal Changes in Tennessee
Ever-Broadening Actions Will Increase Prescription Drug Spending by Nearly $5 Billion (Nashville, TN) — The Pharmaceutical Care Management Association (PCMA) today released a report finding that recent
PCMA Report Details What PBMs Are Doing to Improve Health Equity
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new, first-of-its-kind, progress report on the work PCMA member pharmacy benefit companies are
PCMA Statement on CMS Letter to Pharmacy Benefit Companies
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement in response to a letter issued by the Centers for Medicare and Medicaid Services
PCMA Statement On House Vote Of H.R. 5378
The Pharmaceutical Care Management Association (PCMA) released the following statement on the U.S. House of Representatives’ vote on the Lower Costs, More Transparency Act. “America’s
Register Now: December 13: RealClearPolitics Event: The Consequences Of Targeting Pharmacy Benefits
On December 13 at 1 p.m. EST, RealClearPolitics will host a virtual event, “The Consequences of Targeting Pharmacy Benefits.” The event will bring together policymaker
Big Pharma Backed “Delinking” Legislation Threatens to Significantly Increase Prescription Drug Costs in Commercial Market
Economic Analyses Shows “Delinking” Policy Hands Big Pharma a Financial Windfall totaling $32 Billion Annually (Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) issued the
Renewed Congressional Focus On Patent Abuse Touts Proposals to Effectively Lower Prescription Drug Costs, Strengthen Competition in the Market
U.S. Senators Peter Welch (D-VT), Mike Braun (R-IN), and Amy Klobuchar (D-MN) recently introduced legislation that will crack down on drug companies’ patent abuse, specifically patent
ICYMI: 2021 House Oversight Committee Report Concluded Rebates Are Uncorrelated With Drug Prices
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with
ICYMI: Former U.S. Senator Pat Toomey: GOP Can’t Afford to Start 2024 with Giant Health Care Mandates
In case you missed it, former U.S. Senator Pat Toomey (R-PA) warns Republican policymakers against passing unvetted and disastrous policies targeting pharmacy benefits being debated
ICYMI: New Report Underscores That Rebates Have No Correlation With High Drug Prices
In case you missed it, a new report from health policy researcher Alex Brill, founder and CEO of Matrix Global Advisors and former policy director
ICYMI: New Public Employee Policy Research Affirms PBMs Are Essential In Administering Pharmacy Benefits, Public Sector Employers Satisfied With Their Pharmacy Benefit Companies
In case you missed it, the National Institute for Public Employee Health Care Policy recently released a report, “How Public Sector Health Care Purchasers Are
ICYMI: Former Senator Pat Toomey Cautions Congress Against Proposals Targeting Pharmacy Benefit Companies
In case you missed it, WTOP’s Mitchell Miller spoke with former U.S. Senator Pat Toomey (R-PA) about the current health care debate in Congress in
ICYMI: Former Representative Altmire Joins Former U.S. Senator Pat Toomey In Cautioning Lawmakers Against Passing Proposals Targeting Pharmacy Benefits
In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called
ICYMI: “Delinking” Legislation Provides Big Pharma With $32 Billion Bailout Annually While Costing Patients And Families Up To $27 Billion In Increased Premiums
So-called “delinking” policies continue to be discussed in Congress. Among several glaring problems — including a rejection of free market performance-based incentives that lower drug
ICYMI: Employers Choose Spread Pricing for a Reason
Millions of Patients Impacted if Option to Use Spread Pricing is Taken Away Pharmacy benefit companies offer employers and health plans flexibility when they’re designing
ICYMI: JAMA Article Affirms Misguided Policies Targeting Pharmacy Benefit Companies Would Weaken Negotiating Power Against Big Pharma, Undercut Savings
A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a paper,